UPL BENELUX BV

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Years since formation: 3 years; since Sep 15, 2022
Type: Norwegian division of foreign business enterprise
VAT registered: No
Number of employees: 0

Financials

Total operating income 2023: 2,014,359; NOK
Annual total result 2023: 74,819; NOK
Total equity 2023: 74,819; NOK

Last update: Sep 23, 2024

Management

Board

Name	Role	Shares
BA Berit Bjugan Aam 1976	Contact Person	-
U UPL BENELUX BV	Information about the Company in the Home Country	-

Others

Name	Role	Shares
C CSC ACCOUNTING (NORWAY) AS	Accountant	-

Last update: Apr 13, 2023

Ownership

No available data

Financials

in NOK

Summary

Year	2023
Total operating income	2,014,359
Annual Total Result	74,819
Total assets	2,011,149
Total liabilities	1,936,331
Total equity	74,819

P&L

Year	2023
Total operating income	2,014,359
Total operating costs	1,917,691
Operating result	96,668
Financial income/costs	-746
Profit before tax	95,922
Total tax & extraordinary income/cost	21,103
Annual Total Result	74,819

Balance overview

Year	2023
Total fixed assets	-3,210
Total current assets	2,014,359
Total assets	2,011,149
Short term debt	1,936,331
Long term debt	0
Total liabilities	1,936,331
Contributed capital	0
Retained earnings	74,819
Total equity	74,819
Total equity and liabilities	2,011,149

UPL BENELUX BV929 654 218

UPL BENELUX BV

Keywords

Organization

Financials

Management

Board

Others

Ownership

Financials

Summary

P&L

Balance overview

Classification